Article
Oncology
David Restle, Joseph Dux, Xiaoyu Li, Alexander J. Byun, Jennie K. Choe, Yan Li, Raj G. Vaghjiani, Carlos Thomas, Kyohei Misawa, Kay See Tan, David R. Jones, Navin K. Chintala, Prasad S. Adusumilli
Summary: In patients with lung adenocarcinoma, brain metastases have a more immune-suppressive tumor immune microenvironment compared to other metastases. Majority of patients with antigen expression in the primary tumor also have antigen expression in the metastases, although with heterogeneous intensity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Javier Glez-Vaz, Arantza Azpilikueta, Irene Olivera, Assunta Cirella, Alvaro Teijeira, Maria C. Ochoa, Maite Alvarez, Inaki Eguren-Santamaria, Carlos Luri-Rey, Maria E. Rodriguez-Ruiz, Xinxin Nie, Lieping Chen, Sonia Guedan, Miguel F. Sanamed, Jose Luis Perez Gracia, Ignacio Melero
Summary: CD137 agonists have shown efficacy in tumor treatment, and the levels of sCD137 and CD137 surface expression can serve as quantitative parameters for therapeutic activity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
MacLean S. Hall, Jamie K. Teer, Xiaoqing Yu, Holly Branthoover, Sebastian Snedal, Madeline Rodriguez-Valentin, Luz Nagle, Ellen Scott, Ben Schachner, Patrick Innamarato, Amy M. Hall, Jamie Blauvelt, Carolyn J. Rich, Allison D. Richards, Jake Ceccarelli, T. J. Langer, Sean J. Yoder, Matthew S. Beatty, Cheryl A. Cox, Jane L. Messina, Daniel Abate-Daga, James J. Mule, John E. Mullinax, Amod A. Sarnaik, Shari Pilon-Thomas
Summary: This study highlights the importance of neoantigen-specific CD4(+)T cells within tumor-infiltrating lymphocytes (TILs) as a potent source of tumor-specific effectors. The findings suggest that these CD4(+)T cells play a significant role in antitumor immunity and should be included in future adoptive cell therapy (ACT) protocols to improve treatment efficacy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Helena Van Damme, Bruno Dombrecht, Mate Kiss, Heleen Roose, Elizabeth Allen, Eva Van Overmeire, Daliya Kancheva, Liesbet Martens, Aleksandar Murgaski, Pauline Madeleine Rachel Bardet, Gillian Blancke, Maude Jans, Evangelia Bolli, Maria Solange Martins, Yvon Elkrim, James Dooley, Louis Boon, Julia Katharina Schwarze, Frank Tacke, Kiavash Movahedi, Niels Vandamme, Bart Neyns, Sebahat Ocak, Isabelle Scheyltjens, Lars Vereecke, Frank Aboubakar Nana, Pascal Merchiers, Damya Laoui, Jo Agnes Van Ginderachter
Summary: Regulatory T cells (Tregs) play a role in antitumor immunotherapy, but lack of selectivity for tumor-infiltrating Tregs can lead to adverse effects. CCR8-specific nanobodies were developed to selectively deplete tumor-promoting Tregs in mouse and human tumors, synergizing with anti-PD-1 therapy and reducing tumor growth through NK cell-dependent mechanisms. Targeting CCR8 may be an effective and safe strategy for antitumor immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Sarah A. Penny, Jennifer G. Abelin, Stacy A. Malaker, Paisley T. Myers, Abu Z. Saeed, Lora G. Steadman, Dina L. Bai, Stephen T. Ward, Jeffrey Shabanowitz, Donald F. Hunt, Mark Cobbold
Summary: The study found that in colorectal cancer, HLA-I phosphopeptides are important targets for immunotherapy, triggering tumor-resident immunity against malignancy. These phosphopeptides, derived from certain signaling pathways, can potentially lead to the development of broadly applicable therapeutic strategies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Bradley Sinclair White, Sivasish Sindiri, Victoria Hill, Billel Gasmi, Shirley Nah, Jared J. Gartner, Todd D. Prickett, Yong Li, Devikala Gurusamy, Paul Robbins, Steven A. Rosenberg, Vid Leko
Summary: Metastatic cholangiocarcinoma (CC), a type of gastrointestinal cancer, has a poor prognosis and cannot be cured by current therapies. Previous research has shown that adoptive transfer of autologous tumor infiltrating lymphocytes (TILs) that recognize tumor-specific mutations can lead to cancer regression. This study aimed to determine if TILs could recognize FGR2 fusions in patients with CC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Claire Y. Li, Hyeung Ju Park, Jinyeon Shin, Jung Eun Baik, Babak J. Mehrara, Raghu P. Kataru
Summary: This study suggests that lymphatic endothelial cells (LECs) can act as immunosuppressive cells in the tumor microenvironment (TME) in an MHC-II dependent manner. LECs in the TME increase MHC-II expression and co-inhibitory signals, suppressing the immune response. This finding highlights the importance of understanding the role of LECs in tumor immunity and opens up new avenues for therapeutic interventions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Kristen Hurov, Johanna Lahdenranta, Punit Upadhyaya, Eric Haines, Heather Cohen, Elizabeth Repash, Drasti Kanakia, Jun Ma, Julia Kristensson, Fanglei You, Carly Campbell, David Witty, Mike Kelly, Stephen Blakemore, Phil Jeffrey, Kevin McDonnell, Philip Brandish, Nicholas Keen
Summary: The study developed a tumor-targeted CD137 agonist BT7480 that binds to Nectin-4 and CD137, resulting in potent tumor-specific immune cell activation, showing potential therapeutic effects in human cancers.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
David Noyes, Arup Bag, Saheed Oseni, Jon Semidey-Hurtado, Ling Cen, Amod A. Sarnaik, Vernon K. Sondak, Dennis Adeegbe
Summary: This study demonstrates that the accumulation of Tregs contributes to the dysfunction and clonal constriction of tumor-infiltrating CD8 +T cells. The dysfunctional phenotype of CD8 +T cells is reversed upon reduction of Tregs, and this is mediated by Treg-expressed CTLA-4.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Veronica Finisguerra, Tereza Dvorakova, Matteo Formenti, Pierre Van Meerbeeck, Lionel Mignion, Bernard Gallez, Benoit J. van den Eynde
Summary: Despite limitations in certain tumor types and patients, immunotherapies have achieved revolutionary success in cancer treatment. However, the efficacy of immunotherapies is dependent on the viability and functionality of tumor antigen-specific CD8 T cells within the immunosuppressive tumor microenvironment, where oxygen levels are often low. This study reveals that the antidiabetic drug metformin can improve CD8 T cell fitness in hypoxia, increasing their proliferation and cytokine production, and enhancing their infiltration and survival in hypoxic tumor areas. This presents a promising strategy to overcome resistance to immunotherapy in hypoxic and immunosuppressive tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Hee Sang Hwang, Deokhoon Kim, Jene Choi
Summary: The study suggests that the indel mutation burden, rather than total TMB, might be a better predictor of high TILs in both MSI-high and POLE-mutated tumors. Multiple uncharacterized/non-pathogenic POLE mutations in MSI-high tumors may have combined pathogenic roles. Additionally, mutations in the PI3K/AKT/mTOR pathway could serve as a biomarker for immune therapy stratification in advanced MSI-high tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Natalija Van Braeckel-Budimir, Joseph Samuel Dolina, Jie Wei, Xiao Wang, Shih-Hsun Chen, Pamela Santiago, Guanghuan Tu, Luca Micci, Amir A. Al-Khami, Sophia Pfister, Sripad Ram, Purnima Sundar, Graham Thomas, Hua Long, Wenjing Yang, Shobha Potluri, Shahram Salek-Ardakani
Summary: Our study identified distinct CD8(+) T cell subtypes with functional and migratory signatures that predict tumor rejection upon treatment, with OX40/4-1BB agonism expanding a stem-like T cell subpopulation. PD-(L)1 blockade synergized with OX40/4-1BB costimulation by enhancing the presence of stem-like TILs via a CXCR3-dependent mechanism, providing new insights into combinatorial immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Xinyue Li, Jing Yang
Summary: This study investigated the relationship between tumor deposits and clinicopathological characteristics, tumor-infiltrating lymphocytes, and prognosis in gastric cancer. The results showed a significant association between tumor deposits and various characteristics and prognosis of gastric cancer, with patients having more than 4 tumor deposits having a worse prognosis.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Review
Oncology
Yueshui Zhao, Jian Deng, Shuangfeng Rao, Sipeng Guo, Jing Shen, Fukuan Du, Xu Wu, Yu Chen, Mingxing Li, Meijuan Chen, Xiaobing Li, Wanping Li, Li Gu, Yuhong Sun, Zhuo Zhang, Qinglian Wen, Zhangang Xiao, Jing Li
Summary: Cell-based immunotherapy, especially tumor-infiltrating lymphocytes (TILs) therapy, has emerged as a powerful strategy in solid cancer treatment. This review summarizes the current strategies and challenges in TIL generation, and discusses the clinical trials where TIL therapy is used independently or in combination with other therapies for solid tumor treatment. The limitations, future potential, and directions of TIL therapy for solid tumors are also discussed.
Article
Oncology
Diana Rose E. Ranoa, Preeti Sharma, Claire P. Schane, Amber N. Lewis, Edward Valdez, Venkata V. V. R. Marada, Marlies Hager, Will Montgomery, Steven P. Wolf, Karin Schreiber, Hans Schreiber, Keith Bailey, Timothy M. Fan, Paul J. Hergenrother, Edward J. Roy, David M. Kranz
Summary: The use of CAR-T cell therapy against blood cancers has been successful, but its efficacy against solid tumors has been limited. By using a mouse ovarian cancer cell line, researchers found that CAR-T cell therapy can effectively inhibit the growth of solid tumors, with the most effective CAR having the highest affinity for the antigen.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
